Prometic Life to expand clinical trial of PBI-1402 outside U.S.

By Lisa Kerner

Charlotte, N.C., Sept. 13 - Prometic Life Sciences Inc.'s board of directors approved plans to expand the company's phase 1b/2 clinical trial of PBI-1402, an orally active drug targeting anemia, to multiple sites in Canada and Europe.

"This expansion of the PBI-1402 trial sites is one of many initiatives being undertaken to ensure that we will have trial results in 2007 and will, we anticipate, pave the way for further clinical developments," chief executive officer Pierre Laurin said in a company news release.

The Montreal, Quebec-based biopharmaceutical company will also begin clinical trials of PBI-1393 for advanced cervical cancer as it seeks orphan drug status for the drug candidate.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.